Rachel Warren

Rachel Warren

TMFRachelW

Recent articles

Virtual psychologist therapy session

The Top 5 Mental Health Startups of 2020

These five mental health startups offer apps and online services for one-on-one counseling, meditation, mindfulness, and more.


Telehealth consultation 1

Should Teladoc Be Worried About Zocdoc's New Telehealth Service?

Zocdoc has serious disruptor potential.


blue and green pills on conveyer belt

Better Buy: Bristol Myers Squibb vs. Gilead Sciences

Which of these household names is the better buy?


GettyImages-1212407716

Health and Wellness Startup Everlywell Selling At-Home Coronavirus Test Kits for $109

With this self-administered nasal swab test, you can have a confirmed COVID-19 diagnosis in two days or less.


Coronvirus

Moderna Shares Up Almost 250% This Year as Vaccine Trials Continue

This stock is making big moves on the heels of positive interim data from phase 1 human trials of Moderna's COVID-19 vaccine candidate.

GettyImage_StockChart

Better Buy: GlaxoSmithKline vs. Pfizer

Both companies are weathering the bear market well as they lead the race to develop the coronavirus vaccine. But which is the better buy?


Virus spreading pathogens

23andMe Is Trying to Crack the Genetic Code Behind the Coronavirus

The genomics and biotechnology company has launched a comprehensive genetic study in an effort to discover why COVID-19 elicits such an acute response in some patients but not in others.


GettyImages-1216018044

As COVID-19 Rocks Markets, Digital Health Start-Ups Rake In Cash

These three healthcare start-ups have serious disruptor potential.


worker stocking pharmacy shelf

Is Rite Aid Stock a Buy?

Here's why you may want to think twice before scooping up shares.


DoctorsWorkingInLab_GettyImages

Here's Why Investors Should Follow Sanofi and GlaxoSmithKline's New Coronavirus Collaboration

The combined effort of these two companies marks one of the largest manufacturing collaborations on the planet toward a coronavirus vaccine.

GettyImage_StockChart

3 Dividend Stocks Weathering the Coronavirus Storm

These three stocks aren't just surviving the coronavirus storm -- they're thriving in it.


CoronavirusSyringe_GettyImages

Pfizer Gets German Approval To Start COVID-19 Vaccine Human Trials; Potential Treatment Also In The Works.

Pfizer is developing a potential coronavirus treatment and a vaccine candidate. With potential big wins in the near future, is now the time to buy?


Getty Images_Vaccine

Is Moderna a Good Coronavirus Stock To Buy?

This biotech will soon start phase 2 trials of its coronavirus vaccine, marking some of the first human trials among all COVID-19 candidates.


GettyImages_PharmacyWorker

2 Pharmacy Stocks to Buy and Hold Amid the COVID-19 Crisis

If you're not sure where to invest in the bear market, you'll want to take a second look at these two crazy-cheap stocks.


GettyImage_StockChart

Should You Scoop Up Bristol Myers Squibb Shares?

Few stocks have avoided the mass coronavirus sell-off, and Bristol Myers is no exception. Is this cheap stock worth a second look?

GettyImages-1130982608

Biogen Could Score a Major Win if Alzheimer's Drug Gets the Green Light

With high hopes for the approval of its blockbuster Alzheimer's drug, aducanumab, is now a good time to scoop up Biogen shares?


doctor holding heart organ transplant concept

Is CVS a Good Buy Right Now?

CVS has seen remarkable gains over the trailing twelve months, mostly thanks to its nearly $70 billion purchase of Aetna at the end of 2018. Should investors buy now?


doctor holding heart organ transplant concept

Johnson & Johnson Is Racing Against Time to Develop the First Coronavirus Vaccine

In the bid against other big pharma players to be the first to launch the coronavirus vaccine, Johnson & Johnson just announced a new collaboration that will double its efforts.


delayed flight arline airport

Boeing Is Reeling From Major Annual Losses and the 737 Max Debacle — Should Investors Cut and Run?

Boeing experienced a revenue decline of approximately 37 percent in Q4 and total yearly losses of $636 million in 2019. Can it recover in 2020?


financial health stethoscope money cash hundred bills medical healthcare

Is Merck Still a Strong Buy?

Merck shares rose by nearly 19% in 2019. Do the recent regulatory snags with Merck’s cancer-fighting drug Keytruda pose a threat to the company’s future financial health?